Sentence	entity_1	entity_2	entity_3	entity_4	entity_5	entity_6	entity_7	entity_8	entity_9	json	split
"Our data recall the "" feed - forward "" interaction between T - bet and Runx3 that we previously described in CD4 + ( Th1) T cells ( 15) but are distinct in two respects: in differentiating Th1 cells, T - bet is induced by TCR signals and IFN - gamma, and in turn induces Runx3 ( 15), whereas in differentiating CD8 + T cells, preexisting Runx3 is required to induce the T - box transcription factor Eomes."	T - bet,59,66,Protein	Runx3,71,76,Protein	CD4,109,112,Protein	T - bet,200,207,Protein	IFN - gamma,238,249,Protein	Runx3,271,276,Protein	CD8,311,314,Protein	Runx3,338,343,Protein	Eomes,399,404,Protein	"[{""token"": ""T - bet"", ""start_span"": 59, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 71, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 109, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 200, ""end_span"": 207, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 238, ""end_span"": 249, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 271, ""end_span"": 276, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 311, ""end_span"": 314, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 338, ""end_span"": 343, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 399, ""end_span"": 404, ""type"": ""Protein""}]"	train
Runx3 + / + or Runx3 - / - CD8 + T cells were activated and transduced with retroviruses bearing an empty IRES - GFP cassette ( GFP) or also encoding Eomes - VP16 ( Eo - VP16) or Myc - Runx3 ( Runx3).	Runx3,0,5,Protein	Runx3,15,20,Protein	CD8,27,30,Protein	GFP,113,116,Protein	Eomes - VP16,150,162,Protein	Eo - VP16,165,174,Protein	Myc,179,182,Protein	Runx3,185,190,Protein	Runx3,193,198,Protein	"[{""token"": ""Runx3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 15, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 27, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""GFP"", ""start_span"": 113, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""Eomes - VP16"", ""start_span"": 150, ""end_span"": 162, ""type"": ""Protein""}, {""token"": ""Eo - VP16"", ""start_span"": 165, ""end_span"": 174, ""type"": ""Protein""}, {""token"": ""Myc"", ""start_span"": 179, ""end_span"": 182, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 185, ""end_span"": 190, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 193, ""end_span"": 198, ""type"": ""Protein""}]"	train
Th1 cell development requires signal transducer and activator of transcription ( STAT) 1 activation, induced by type I IFN or IFN - gamma, the transcription factor T - box 21 ( T - bet), and IL - 12 - induced STAT4 signaling, which can couple with IL - 18 - induced IRAK and NF - kappaB transcription factors to drive the high amounts of IFN - gamma required to eradicate intracellular pathogens ( Glimcher and Murphy, 2000).	type I IFN,112,122,Protein	IFN - gamma,126,137,Protein	T - box 21,164,174,Protein	T - bet,177,184,Protein	IL - 12,191,198,Protein	STAT4,209,214,Protein	IL - 18,248,255,Protein	IRAK,266,270,Protein	IFN - gamma,338,349,Protein	"[{""token"": ""type I IFN"", ""start_span"": 112, ""end_span"": 122, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 126, ""end_span"": 137, ""type"": ""Protein""}, {""token"": ""T - box 21"", ""start_span"": 164, ""end_span"": 174, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 177, ""end_span"": 184, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 191, ""end_span"": 198, ""type"": ""Protein""}, {""token"": ""STAT4"", ""start_span"": 209, ""end_span"": 214, ""type"": ""Protein""}, {""token"": ""IL - 18"", ""start_span"": 248, ""end_span"": 255, ""type"": ""Protein""}, {""token"": ""IRAK"", ""start_span"": 266, ""end_span"": 270, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 338, ""end_span"": 349, ""type"": ""Protein""}]"	train
Mutant BMDC had defective activation of NF - kappaB signaling, whereas the MAPK1 / 3 ( ERK1 / 2) and MAPK11 / 12 / 13 / 14 ( p38 MAP kinase isoforms) and TBK1 signaling pathways were intact.	MAPK1,75,80,Protein	3,83,84,Protein	ERK1,87,91,Protein	2,94,95,Protein	MAPK11,101,107,Protein	12,110,112,Protein	13,115,117,Protein	14,120,122,Protein	TBK1,154,158,Protein	"[{""token"": ""MAPK1"", ""start_span"": 75, ""end_span"": 80, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 83, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""ERK1"", ""start_span"": 87, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 94, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""MAPK11"", ""start_span"": 101, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""12"", ""start_span"": 110, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""13"", ""start_span"": 115, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""14"", ""start_span"": 120, ""end_span"": 122, ""type"": ""Protein""}, {""token"": ""TBK1"", ""start_span"": 154, ""end_span"": 158, ""type"": ""Protein""}]"	train
Immunoblots were performed with antibodies ( Cell Signaling Technology) against p - IKK1 / 2 ( # 2697), p - IkappaBalpha ( # 9246), IkappaBalpha ( # 4814), p - TBK1 ( # 5483), p - p38 ( # 9216), p38 ( # 9212), p - ERK1 / 2 ( # 4376), and ERK1 / 2 ( # 4695).	IKK1,84,88,Protein	2,91,92,Protein	IkappaBalpha,108,120,Protein	IkappaBalpha,132,144,Protein	TBK1,160,164,Protein	ERK1,214,218,Protein	2,221,222,Protein	ERK1,238,242,Protein	2,245,246,Protein	"[{""token"": ""IKK1"", ""start_span"": 84, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 91, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""IkappaBalpha"", ""start_span"": 108, ""end_span"": 120, ""type"": ""Protein""}, {""token"": ""IkappaBalpha"", ""start_span"": 132, ""end_span"": 144, ""type"": ""Protein""}, {""token"": ""TBK1"", ""start_span"": 160, ""end_span"": 164, ""type"": ""Protein""}, {""token"": ""ERK1"", ""start_span"": 214, ""end_span"": 218, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 221, ""end_span"": 222, ""type"": ""Protein""}, {""token"": ""ERK1"", ""start_span"": 238, ""end_span"": 242, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 245, ""end_span"": 246, ""type"": ""Protein""}]"	train
The CD4 + CD25 -, CD45RA +, CD45RO +, and CD4 + CD45RO + CD25 - were able to significantly induce FOXP3 mRNA up to 30 - fold upon TCR activation and addition of TGF - beta.	CD4,4,7,Protein	CD25,10,14,Protein	CD45RA,18,24,Protein	CD45RO,28,34,Protein	CD4,42,45,Protein	CD45RO,48,54,Protein	CD25,57,61,Protein	FOXP3,98,103,Protein	TGF - beta,161,171,Protein	"[{""token"": ""CD4"", ""start_span"": 4, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 10, ""end_span"": 14, ""type"": ""Protein""}, {""token"": ""CD45RA"", ""start_span"": 18, ""end_span"": 24, ""type"": ""Protein""}, {""token"": ""CD45RO"", ""start_span"": 28, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 42, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""CD45RO"", ""start_span"": 48, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 57, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 98, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 161, ""end_span"": 171, ""type"": ""Protein""}]"	valid
Upon administration of rmIL - 4 plus anti - IL - 4 mAb complexes, the total number of CD4 + CD25 + T cell, as well as the Foxp3 + T cells diminished by half ( Figure S2G and S2H), confirming that the lower percentage was not due to an increase in the CD4 + CD25 - cells, but a real decrease of CD4 + CD25 + T cells.	rmIL - 4,23,31,Protein	IL - 4,44,50,Protein	CD4,86,89,Protein	CD25,92,96,Protein	Foxp3,122,127,Protein	CD4,251,254,Protein	CD25,257,261,Protein	CD4,294,297,Protein	CD25,300,304,Protein	"[{""token"": ""rmIL - 4"", ""start_span"": 23, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 44, ""end_span"": 50, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 86, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 92, ""end_span"": 96, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 122, ""end_span"": 127, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 251, ""end_span"": 254, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 257, ""end_span"": 261, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 294, ""end_span"": 297, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 300, ""end_span"": 304, ""type"": ""Protein""}]"	valid
CD4 + T cells were gated on the basis of CD45RO and CD25 surface expression ( upper panel), and gated cells are shown below for the CD45RO + CD25 - ( A, left panel), the CD45RO + CD25 + ( right panel), and the CD45RO - CD25 - subsets ( central panel).	CD4,0,3,Protein	CD45RO,41,47,Protein	CD25,52,56,Protein	CD45RO,132,138,Protein	CD25,141,145,Protein	CD45RO,170,176,Protein	CD25,179,183,Protein	CD45RO,210,216,Protein	CD25,219,223,Protein	"[{""token"": ""CD4"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""CD45RO"", ""start_span"": 41, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 52, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""CD45RO"", ""start_span"": 132, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 141, ""end_span"": 145, ""type"": ""Protein""}, {""token"": ""CD45RO"", ""start_span"": 170, ""end_span"": 176, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 179, ""end_span"": 183, ""type"": ""Protein""}, {""token"": ""CD45RO"", ""start_span"": 210, ""end_span"": 216, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 219, ""end_span"": 223, ""type"": ""Protein""}]"	valid
Human CD4 + CD127 - CD25high and CD4 + CD127 + CD25neg cells were purified by flow cytometry using anti - CD127, anti - CD25 - PC5 ( Beckman Coulter), and anti - CD4 - FITC antibodies ( Dako).	CD4,6,9,Protein	CD127,12,17,Protein	CD25high,20,28,Protein	CD4,33,36,Protein	CD127,39,44,Protein	CD25neg,47,54,Protein	CD127,106,111,Protein	CD25,120,124,Protein	CD4,162,165,Protein	"[{""token"": ""CD4"", ""start_span"": 6, ""end_span"": 9, ""type"": ""Protein""}, {""token"": ""CD127"", ""start_span"": 12, ""end_span"": 17, ""type"": ""Protein""}, {""token"": ""CD25high"", ""start_span"": 20, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 33, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""CD127"", ""start_span"": 39, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""CD25neg"", ""start_span"": 47, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""CD127"", ""start_span"": 106, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 120, ""end_span"": 124, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 162, ""end_span"": 165, ""type"": ""Protein""}]"	valid
( A) RUNX1, RUNX3, and FOXP3 mRNA induction in human naive CD4 + T cells after alone or combined anti - CD2 / 3 / 28 mAb and TGF - beta stimulation in the presence of IL - 2.	RUNX1,5,10,Protein	RUNX3,12,17,Protein	FOXP3,23,28,Protein	CD4,59,62,Protein	CD2,104,107,Protein	3,110,111,Protein	28,114,116,Protein	TGF - beta,125,135,Protein	IL - 2,167,173,Protein	"[{""token"": ""RUNX1"", ""start_span"": 5, ""end_span"": 10, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 12, ""end_span"": 17, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 23, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 59, ""end_span"": 62, ""type"": ""Protein""}, {""token"": ""CD2"", ""start_span"": 104, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 110, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""28"", ""start_span"": 114, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 125, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 167, ""end_span"": 173, ""type"": ""Protein""}]"	valid
Real - time PCR for FOXP3, T - bet, GATA3, and RORC2 from human naive CD4 + T cells, transfected with RUNX1 and RUNX3 siRNA or with scrambled siRNA ( control) and cultured under iT reg, Th1, Th2, or Th17 - driving conditions for 12 d.	FOXP3,20,25,Protein	T - bet,27,34,Protein	GATA3,36,41,Protein	RORC2,47,52,Protein	CD4,70,73,Protein	RUNX1,102,107,Protein	RUNX3,112,117,Protein	iT reg,178,184,Protein	Th17,199,203,Protein	"[{""token"": ""FOXP3"", ""start_span"": 20, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 27, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 36, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""RORC2"", ""start_span"": 47, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 70, ""end_span"": 73, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 102, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 112, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""iT reg"", ""start_span"": 178, ""end_span"": 184, ""type"": ""Protein""}, {""token"": ""Th17"", ""start_span"": 199, ""end_span"": 203, ""type"": ""Protein""}]"	valid
Coimmunoprecipitation of IkappaB - alpha with p65 was detected at 0 - and 240 - min post - treatment in Tat - negative cells ( Figure 2D, lanes 1 and 3), and was halved in Tat - positive cells, where Tat coimmunoprecipitated with IkappaB - alpha ( Figure 2D, lanes 2 and 4), indicating that Tat competed the IkappaB - alpha binding to p65.	IkappaB - alpha,25,40,Protein	p65,46,49,Protein	Tat,104,107,Protein	Tat,172,175,Protein	Tat,200,203,Protein	IkappaB - alpha,230,245,Protein	Tat,291,294,Protein	IkappaB - alpha,308,323,Protein	p65,335,338,Protein	"[{""token"": ""IkappaB - alpha"", ""start_span"": 25, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 46, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 104, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 172, ""end_span"": 175, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 200, ""end_span"": 203, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 230, ""end_span"": 245, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 291, ""end_span"": 294, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 308, ""end_span"": 323, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 335, ""end_span"": 338, ""type"": ""Protein""}]"	valid
Further, we analysed the Tat effect on the IkappaB - alpha repression of p65 transcriptional activity by transfecting p50 - / - p65 - / - MEFs with the NF - kappaB - Luc reporter together with expression vectors of p65 and IkappaB - alpha, in presence or absence of Tat.	Tat,25,28,Protein	IkappaB - alpha,43,58,Protein	p65,73,76,Protein	p50,118,121,Protein	p65,128,131,Protein	Luc,166,169,Protein	p65,215,218,Protein	IkappaB - alpha,223,238,Protein	Tat,266,269,Protein	"[{""token"": ""Tat"", ""start_span"": 25, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 43, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 73, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""p50"", ""start_span"": 118, ""end_span"": 121, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 128, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""Luc"", ""start_span"": 166, ""end_span"": 169, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 215, ""end_span"": 218, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 223, ""end_span"": 238, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 266, ""end_span"": 269, ""type"": ""Protein""}]"	valid
Similarly to MIP - 1alpha, Tat increased the recruitment of p65 to the NF - kappaB enhancers of CSF3, LTA, NFKBIA and TLR2, while it was ineffective at the promoters of GAPDH and ACTB ( Figure 5H).	MIP - 1alpha,13,25,Protein	Tat,27,30,Protein	p65,60,63,Protein	CSF3,96,100,Protein	LTA,102,105,Protein	NFKBIA,107,113,Protein	TLR2,118,122,Protein	GAPDH,169,174,Protein	ACTB,179,183,Protein	"[{""token"": ""MIP - 1alpha"", ""start_span"": 13, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 27, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 60, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""CSF3"", ""start_span"": 96, ""end_span"": 100, ""type"": ""Protein""}, {""token"": ""LTA"", ""start_span"": 102, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""NFKBIA"", ""start_span"": 107, ""end_span"": 113, ""type"": ""Protein""}, {""token"": ""TLR2"", ""start_span"": 118, ""end_span"": 122, ""type"": ""Protein""}, {""token"": ""GAPDH"", ""start_span"": 169, ""end_span"": 174, ""type"": ""Protein""}, {""token"": ""ACTB"", ""start_span"": 179, ""end_span"": 183, ""type"": ""Protein""}]"	valid
In part, this change may be caused by GP - mediated modulations of the TSST - 1 induced binding of NFkappaB, NFIL - 6 and NFAT to known and up to now unknown sites within the IL - 8 and IL - 1RA promoter instead of the TNFalpha, IL - 1beta, IL - 6 or IFNgamma promoter.	TSST - 1,71,79,Protein	NFIL - 6,109,117,Protein	NFAT,122,126,Protein	IL - 8,175,181,Protein	IL - 1RA,186,194,Protein	TNFalpha,219,227,Protein	IL - 1beta,229,239,Protein	IL - 6,241,247,Protein	IFNgamma,251,259,Protein	"[{""token"": ""TSST - 1"", ""start_span"": 71, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""NFIL - 6"", ""start_span"": 109, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""NFAT"", ""start_span"": 122, ""end_span"": 126, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 175, ""end_span"": 181, ""type"": ""Protein""}, {""token"": ""IL - 1RA"", ""start_span"": 186, ""end_span"": 194, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 219, ""end_span"": 227, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 229, ""end_span"": 239, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 241, ""end_span"": 247, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 251, ""end_span"": 259, ""type"": ""Protein""}]"	test
To determine whether the DNA binding proteins were related to NFkappaB and NFAT, dot blots using a SRC96D SNS minifold I dot blotter ( Schleicher & Schull, Dassel, Germany) were performed with the following positive controls and antibodies ( all from Santa Cruz Biotechnology, Heidelberg, Germany): positive controls ( 10 ng / dot): NFkappaB p52 ( 80 kD) sc - 4095WB, c - Rel ( 61 kD) sc - 4030WB; Jurkat nuclear extract, PMA - stimulated; primary antibodies ( 1 mug / dot): anti - NFkappaB p50 ( NLS) sc - 114, anti - NFkappaB p65 ( A) sc - 109, anti - NFkappaB p52 ( 447) sc - 848, a rabbit polyclonal IgG1 antiserum, anti - c - rel ( N466) sc - 272, anti - NFATc2 ( M - 20) sc - 1151, anti - NFATc1 ( K - 18) sc - 1149, two goat polyclonal IgG1 antisera; secondary antibodies ( 0. 8 mug / dot): goat anti - rabbit IgG AP - conjugate sc - 2007, and donkey anti - goat IgG AP - conjugate sc - 2022.	NFAT,75,79,Protein	p52,342,345,Protein	c - Rel,368,375,Protein	p50,491,494,Protein	p65,528,531,Protein	p52,563,566,Protein	c - rel,627,634,Protein	NFATc2,660,666,Protein	NFATc1,695,701,Protein	"[{""token"": ""NFAT"", ""start_span"": 75, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""p52"", ""start_span"": 342, ""end_span"": 345, ""type"": ""Protein""}, {""token"": ""c - Rel"", ""start_span"": 368, ""end_span"": 375, ""type"": ""Protein""}, {""token"": ""p50"", ""start_span"": 491, ""end_span"": 494, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 528, ""end_span"": 531, ""type"": ""Protein""}, {""token"": ""p52"", ""start_span"": 563, ""end_span"": 566, ""type"": ""Protein""}, {""token"": ""c - rel"", ""start_span"": 627, ""end_span"": 634, ""type"": ""Protein""}, {""token"": ""NFATc2"", ""start_span"": 660, ""end_span"": 666, ""type"": ""Protein""}, {""token"": ""NFATc1"", ""start_span"": 695, ""end_span"": 701, ""type"": ""Protein""}]"	test
Whereas the majority of IkappaBs ( IkappaBalpha, IkappaBbeta, IkappaBepsilon, p105 ( also known as NF - kappaB1), p100 ( also known as NF - kappaB2)) serve as inhibitors of NF - kappaB, IkappaBxi and Bcl - 3 instead potentiate NF - kappaB transactivation in the nucleus.	IkappaBalpha,35,47,Protein	IkappaBbeta,49,60,Protein	IkappaBepsilon,62,76,Protein	p105,78,82,Protein	NF - kappaB1,99,111,Protein	p100,114,118,Protein	NF - kappaB2,135,147,Protein	IkappaBxi,186,195,Protein	Bcl - 3,200,207,Protein	"[{""token"": ""IkappaBalpha"", ""start_span"": 35, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""IkappaBbeta"", ""start_span"": 49, ""end_span"": 60, ""type"": ""Protein""}, {""token"": ""IkappaBepsilon"", ""start_span"": 62, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""p105"", ""start_span"": 78, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""NF - kappaB1"", ""start_span"": 99, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""p100"", ""start_span"": 114, ""end_span"": 118, ""type"": ""Protein""}, {""token"": ""NF - kappaB2"", ""start_span"": 135, ""end_span"": 147, ""type"": ""Protein""}, {""token"": ""IkappaBxi"", ""start_span"": 186, ""end_span"": 195, ""type"": ""Protein""}, {""token"": ""Bcl - 3"", ""start_span"": 200, ""end_span"": 207, ""type"": ""Protein""}]"	test
For example, TLR4 stimulation by lipopolysaccharide induces the recruitment of Toll / IL - 1 receptor adaptor protein ( also referred to as Mal) and TRIF - related adaptor molecule ( TRAM), which most probably serve as bridging factors to recruit myeloid differentiation primary response gene 88 ( MyD88) and TIR domain - containing adaptor - inducing IFNbeta ( TRIF), respectively.	TLR4,13,17,Protein	Toll / IL - 1 receptor adaptor protein,79,117,Protein	Mal,140,143,Protein	TRIF - related adaptor molecule,149,180,Protein	TRAM,183,187,Protein	myeloid differentiation primary response gene 88,247,295,Protein	MyD88,298,303,Protein	TIR domain - containing adaptor - inducing IFNbeta,309,359,Protein	TRIF,362,366,Protein	"[{""token"": ""TLR4"", ""start_span"": 13, ""end_span"": 17, ""type"": ""Protein""}, {""token"": ""Toll / IL - 1 receptor adaptor protein"", ""start_span"": 79, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""Mal"", ""start_span"": 140, ""end_span"": 143, ""type"": ""Protein""}, {""token"": ""TRIF - related adaptor molecule"", ""start_span"": 149, ""end_span"": 180, ""type"": ""Protein""}, {""token"": ""TRAM"", ""start_span"": 183, ""end_span"": 187, ""type"": ""Protein""}, {""token"": ""myeloid differentiation primary response gene 88"", ""start_span"": 247, ""end_span"": 295, ""type"": ""Protein""}, {""token"": ""MyD88"", ""start_span"": 298, ""end_span"": 303, ""type"": ""Protein""}, {""token"": ""TIR domain - containing adaptor - inducing IFNbeta"", ""start_span"": 309, ""end_span"": 359, ""type"": ""Protein""}, {""token"": ""TRIF"", ""start_span"": 362, ""end_span"": 366, ""type"": ""Protein""}]"	test
Upon binding of their ligand, CD40 and RANK interact with several TRAF members, including TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6, and this leads to the proteolysis of both TRAF2 and TRAF3, which represents an important step in the activation of the noncanonical pathway as described above.	CD40,30,34,Protein	RANK,39,43,Protein	TRAF1,90,95,Protein	TRAF2,97,102,Protein	TRAF3,104,109,Protein	TRAF5,111,116,Protein	TRAF6,122,127,Protein	TRAF2,171,176,Protein	TRAF3,181,186,Protein	"[{""token"": ""CD40"", ""start_span"": 30, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""RANK"", ""start_span"": 39, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""TRAF1"", ""start_span"": 90, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 97, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 104, ""end_span"": 109, ""type"": ""Protein""}, {""token"": ""TRAF5"", ""start_span"": 111, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 122, ""end_span"": 127, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 171, ""end_span"": 176, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 181, ""end_span"": 186, ""type"": ""Protein""}]"	test
CYLD is a deubiquitinating enzyme that negatively regulates NF - kappaB signalling initiated by TNFR, RANK and T - cell receptor stimulation ( reviewed in [ 64]) ( Figure 1), by deubiquitina - ting several NF - kappaB signalling proteins including NEMO, TRAF2, TRAF6, TRAF7, RIP1 and TAK1.	CYLD,0,4,Protein	deubiquitinating enzyme,10,33,Protein	RANK,102,106,Protein	NEMO,248,252,Protein	TRAF2,254,259,Protein	TRAF6,261,266,Protein	TRAF7,268,273,Protein	RIP1,275,279,Protein	TAK1,284,288,Protein	"[{""token"": ""CYLD"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""deubiquitinating enzyme"", ""start_span"": 10, ""end_span"": 33, ""type"": ""Protein""}, {""token"": ""RANK"", ""start_span"": 102, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""NEMO"", ""start_span"": 248, ""end_span"": 252, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 254, ""end_span"": 259, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 261, ""end_span"": 266, ""type"": ""Protein""}, {""token"": ""TRAF7"", ""start_span"": 268, ""end_span"": 273, ""type"": ""Protein""}, {""token"": ""RIP1"", ""start_span"": 275, ""end_span"": 279, ""type"": ""Protein""}, {""token"": ""TAK1"", ""start_span"": 284, ""end_span"": 288, ""type"": ""Protein""}]"	test
Although CD86 gene expression did not depend on MyD88 ( Figure 7B), abrogation of IRAK1 and TRAF6 gene expression significantly reduced CD86 mRNA levels, indicating that CD86 expression is IRAK1 - and TRAF6 - dependent, but MyD88 - independent in MTb - infected monocytes ( Figures 7C - 7D).	CD86,9,13,Protein	MyD88,48,53,Protein	IRAK1,82,87,Protein	TRAF6,92,97,Protein	CD86,136,140,Protein	CD86,170,174,Protein	IRAK1,189,194,Protein	TRAF6,201,206,Protein	MyD88,224,229,Protein	"[{""token"": ""CD86"", ""start_span"": 9, ""end_span"": 13, ""type"": ""Protein""}, {""token"": ""MyD88"", ""start_span"": 48, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 82, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 92, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""CD86"", ""start_span"": 136, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""CD86"", ""start_span"": 170, ""end_span"": 174, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 189, ""end_span"": 194, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 201, ""end_span"": 206, ""type"": ""Protein""}, {""token"": ""MyD88"", ""start_span"": 224, ""end_span"": 229, ""type"": ""Protein""}]"	test
